



Company Announcement

Nykode Therapeutics to Present New Data and Participate in Panel Discussion at the 9th Annual Antigen-Specific Immune Tolerance Summit (ASIT)

Oslo, Norway, March 3, 2026 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announces that it will play an active role at the upcoming 9th Antigen-Specific Immune Tolerance Summit (ASIT) in Boston on March 3-5, 2026, with both an oral presentation, a scientific poster, and participation in a panel discussion.

At the conference, Nykode will present new preclinical data further validating its proprietary immunotherapy platform. The data demonstrate that selectively targeting distinct antigen-presenting cell (APC) receptors can meaningfully influence both the strength and the quality of immune responses. Importantly, these findings have now been shown in murine models and in human cell systems.

These results support the core design of Nykode's technology, which is built to precisely direct immune responses through APC targeting. The ability to tailor the immune response to specific diseases has broad implications across oncology and autoimmune disorders and reinforces the platform's versatility.

In addition to presenting new data, Nykode will contribute to a scientific panel discussion, highlighting the company's thought leadership and active engagement within the immune tolerance community.

"We are pleased to share additional data supporting the flexibility and power of our platform and to contribute to the broader scientific dialogue in the field," said Agnete Fredriksen, CSO and Co-founder of Nykode Therapeutics.

Further details on presentation timing will be made available through the conference program.

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are abi-suva, a therapeutic immunotherapy for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of late-line r/m cervical cancer. Abi-suva is currently being further developed in head and neck cancer. VB10.NEO, an individualized cancer neoantigen immunotherapy, has been investigated in two trials with more than 10 different indications.



Nykode is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at <http://www.nykode.com>.

Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:

IR@nykode.com

Nykode Therapeutics ASA

Oslo Science Park
Gautstadalléen 21
N-0349 Oslo, Norway